AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:23 2024-05-03 am EDT			5-day change	1st Jan Change
12,050 ^GBX	-0.87%		+0.22%	+13.68%

May. 06	Cellectis: alliance with AstraZeneca finalized	CF
May. 06	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	MT

ASTRAZENECA : UBS remains a Sell rating

April 29, 2020 at 07:12 am EDT

UBS's analyst Michael Leuchten maintains his Sell rating on the stock. The target price is still set at GBp 6000.

Latest news about AstraZeneca PLC

Cellectis: alliance with AstraZeneca finalized	May. 06	CF
Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca	May. 06	MT
AstraZeneca: equity investment in Cellectis	May. 06	CF
AstraZeneca completes collaboration and investment deal with Cellectis	May. 06	AN
AstraZeneca Secures 44% Stake in French Biotech Cellectis	May. 06	MT
Angle shares up on assay development deal with AstraZeneca	May. 03	AN
Angle shares up on assay development deal with AstraZenaca	May. 03	AN
Angle Plc to Supply Prostate Cancer Androgen Receptor Detection Assay to AstraZeneca	May. 03	MT
AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal	May. 03	AN
Confident start before US jobs data	May. 03	AN
InterContinental Hotels makes first-quarter progress	May. 03	AN
AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial	May. 02	MT
AstraZeneca: research into respiratory diseases	May. 02	CF
AstraZeneca Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca PLC Announces Positive High-Level Results from an Interim Analysis of the Echo Phase III Trial	May. 02	CI
AstraZeneca: encouraging results in lymphoma	May. 02	CF
AstraZeneca notes positive trial results for Calquence treatment	May. 02	AN
AstraZeneca's Blood Cancer Combo Extends Progression-free Survival in Late-stage Study	May. 02	MT
Ipsen: new President for North America	May. 02	CF
AstraZeneca PLC Announces Calquence combination improved PFS in 1L MCL	May. 02	CI
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT
FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications	Apr. 30	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-05-19 - American Thoracic Society International Conference - Abstarct Number - P297

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

151.2 USD

Average target price

163.6 USD

Spread / Average Target

+8.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.68%	234B
ELI LILLY AND COMPANY	+31.52%	662B
NOVO NORDISK A/S	+21.96%	546B
JOHNSON & JOHNSON	-5.21%	359B
MERCK & CO., INC.	+17.02%	323B
ABBVIE INC.	+5.01%	289B
NOVARTIS AG	+3.81%	198B
ROCHE HOLDING AG	-10.63%	194B
AMGEN INC.	+3.98%	167B
PFIZER, INC.	-2.19%	157B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : UBS remains a Sell rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals